Dr. Marcus John Mittelsteadt, MD

Dr. Mittelsteadt practices at Infinite Health Collaborative, PA in Wyoming, Minnesota.

Dr. Mittelsteadt's NPI, 1215347117, was assigned on April 30, 2014. Dr. Mittelsteadt graduated from Creighton University School of Medicine in 2014. Dr. Mittelsteadt holds Minnesota license 67925.

Dr. Mittelsteadt's primary practice is Infinite Health Collaborative, PA, at 5130 Fairview Blvd, Wyoming, MN 55092 in Chisago County. The practice phone is (952) 512-5600.

Dr. Mittelsteadt's primary practice is Infinite Health Collaborative, PA in Wyoming, Minnesota. Dr. Mittelsteadt is also affiliated with Mercy Hospital. The medical group on file is Infinite Health Collaborative (i-Health). Dmand AI also links Dr. Mittelsteadt to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mittelsteadt practices, 3 sites in all. Vendor and product names are available with a free account.

Orthopaedic surgery is Dr. Mittelsteadt's primary specialty in the NPI Registry, under taxonomy code 207X00000X. Dmand AI has Dr. Mittelsteadt's licenses on file in 2 states: Minnesota and Michigan.

CMS data shows 5,767 Medicare services from Dr. Mittelsteadt across 13 procedure codes in 2024, for 234 Medicare patients. Medicare paid $32,101 for them. Every service was in an office.

CMS counts 234 Medicare patients who saw Dr. Mittelsteadt in 2024. The largest group is 65 to 74, with 115 patients. 71% of them have arthritis, and 68% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.10, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mittelsteadt's median patient age at 55, with 60% women.

In 2024, Dr. Mittelsteadt wrote 93 Medicare Part D claims for 72 patients. 99% of them were for generic drugs. CMS names the drug for 66 of them, across 3 drugs with 11 or more claims each, at $298 in total drug cost. In 2023, CMS named 22 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Mittelsteadt for performance year 2024, reported as part of a group. Dr. Mittelsteadt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mittelsteadt as offering telehealth.

Knee replacement: 1 to 10 procedures (CMS shows small counts as a range)

Lower limb (leg) arthroscopy (minimally invasive joint repair): 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 3 papers to Dr. Mittelsteadt, published from 2018 to 2022. Dr. Mittelsteadt's most frequent co-authors are Robert A. Arciero, MD, Eric M. Rohman, MD and Marc Tompkins, MD.

CMS Open Payments shows 100 general payments to Dr. Mittelsteadt from 10 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 48% of the total. Stryker Corporation paid the most, $5,230.

Dr. Mittelsteadt graduated from Creighton University School of Medicine in 2014.